摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 2-amino-6-iodobenzoate | 147494-20-0

中文名称
——
中文别名
——
英文名称
methyl 2-amino-6-iodobenzoate
英文别名
methyl 6-iodoanthranilate
methyl 2-amino-6-iodobenzoate化学式
CAS
147494-20-0
化学式
C8H8INO2
mdl
——
分子量
277.062
InChiKey
WLALCEBDEFFUEC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    319.5±27.0 °C(Predicted)
  • 密度:
    1.826±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.12
  • 拓扑面积:
    52.3
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 2-amino-6-iodobenzoatesodium methylate三乙胺 作用下, 以 甲醇二氯甲烷 为溶剂, 生成 4-Hydroxy-5-iodo-2-oxo-1,2-dihydro-quinoline-3-carboxylic acid methyl ester
    参考文献:
    名称:
    Design, synthesis and In vitro evaluation of potent, novel, small molecule inhibitors of plasminogen activator inhibitor-1
    摘要:
    We have synthesized and evaluated a series of tetramic acid-based and hydroxvquinolinone-based inhibitors of plasminogen activator inhibitor-1 (PAI-1). These studies resulted in the identification of several compounds which showed excellent potency against PAI-1. The design, synthesis and SAR of these compounds are described. (C) 2002 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0960-894x(02)00078-1
  • 作为产物:
    参考文献:
    名称:
    Pyridazinedione compounds useful in treating neurological disorders
    摘要:
    本发明涉及吡啶并[4,5-b]喹啉及其药用盐,它们是兴奋性氨基酸拮抗剂,在需要此类拮抗作用时非常有用,例如在治疗神经系统疾病时。该发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的药物组合物,以及治疗神经系统疾病的方法。
    公开号:
    US05599814A1
点击查看最新优质反应信息

文献信息

  • Nickel boride reduction of aryl nitro compounds
    作者:Herbert H. Seltzman、Bertold D. Berrang
    DOI:10.1016/s0040-4039(00)93385-9
    日期:1993.5
    Nickel boride smoothly reduces aryl nitro compounds to the corresponding anilines in the presence of iodo and ortho carboalkoxy groups in contrast to the problematic reductions by other methods.
    硼化镍在存在碘和邻碳烷氧基基团的情况下将芳基硝基化合物平稳地还原为相应的苯胺,这与其他方法难以实现的还原相反。
  • Pyridazinedione compounds useful in the treating neurological disorders
    申请人:Imperial Chemical Industries PLC
    公开号:US05733910A1
    公开(公告)日:1998-03-31
    The present invention relates to pyridazino\x9b4,5-b!quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino\x9b4,5-b!quinolines as active ingredient, and methods for the treatment of neurological disorders.
    本发明涉及吡啶并[4,5-b]喹啉及其药用盐,其为兴奋性氨基酸拮抗剂,在需要这种拮抗作用时,如治疗神经系统疾病时,具有有用性。本发明还提供含有吡啶并[4,5-b]喹啉作为活性成分的制药组合物,以及治疗神经系统疾病的方法。
  • LABELLED ANALOGUES OF HALOBENZAMIDES AS RADIOPHARMACEUTICALS
    申请人:Madelmont Jean-Claude
    公开号:US20100061928A1
    公开(公告)日:2010-03-11
    The present invention relates to the use of a compound of formula (I): in which R 1 represents a radionuclide, Ar represents an aromatic nucleus, m is an integer varying from 2 to 4, R 2 and R 3 represent, independently of one another, a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 )alkenyl group or an aryl group chosen from a phenyl, benzyl, imidazolyl, pyridyl, pyrimidinyl, pyrazinyl, indolyl, indazolyl, furyl and thienyl group, and their addition salts with pharmaceutically acceptable acids, in the preparation of a radiopharmaceutical composition intended for the diagnosis and/or treatment of melanoma.
    本发明涉及使用式(I)化合物:其中R1代表放射性核素,Ar代表芳香环,m为2到4的整数,R2和R3代表独立的氢原子,(C1-C6)烷基,(C1-C6)烯基或苯基,所述苯基选择自苯基,苄基,咪唑基,吡啶基,嘧啶基,吡嗪基,吲哚基,吲唑基,呋喃基和噻吩基,并且它们与药学上可接受的酸的加成盐,用于制备放射性药物组合物,用于诊断和/或治疗黑色素瘤。
  • LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS
    申请人:Chezal Jean-Michel
    公开号:US20110044899A1
    公开(公告)日:2011-02-24
    A compound of formula (I): in which R 1 represents a hydrogen atom, an optionally labelled halogen, a radionuclide or a Sn[(C 1 -C 4 )alkyl] 3 group, Ar represents an aryl group or a heteroaryl group, R 9 represents a hydrogen atom, a (C 1 -C 4 ) alkyl group or forms together with the group R 1 —Ar a ring fused with the Ar group, A represents a group of formula (β) or (δ): R 3 and R 4 independently represent a hydrogen atom, a (C 1 -C 6 )alkyl group, a (C 1 -C 6 ) alkenyl group or a group of formula (y): wherein R 11 represents an optionally labelled halogen, a radionuclide, an aryl or heteroaryl group optionally substituted by an optionally labelled halogen, a radionuclide, a —NO 2 group, a —NR 5 R 6 group, a N + R 5 R 6 R 7 X − group, or a —OSO 2 R 12 group, and their addition salts with pharmaceutically acceptable acids.
    化合物的化学式为(I):其中R1代表氢原子、可选择标记的卤素、放射性核素或Sn[(C1-C4)烷基]3基团,Ar代表芳基或杂芳基,R9代表氢原子、(C1-C4)烷基或与基团R1-Ar共同形成与Ar基团融合的环,A代表化学式(β)或(δ)的基团:R3和R4分别独立地代表氢原子、(C1-C6)烷基、(C1-C6)烯基或化学式(y)的基团:其中R11代表可选择标记的卤素、放射性核素、可选择取代的芳基或杂芳基,取代基可以是可选择标记的卤素、放射性核素、—NO2基团、—NR5R6基团、N+R5R6R7X−基团或—OSO2R12基团,以及它们与药物可接受的酸形成的加合物。
  • Pyridazinediones and their use in the treatment of neurological disorders
    申请人:ZENECA LIMITED
    公开号:EP0516297A1
    公开(公告)日:1992-12-02
    The present invention relates to pyridazino[4,5-b]quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]quinolines as active ingredient, and methods for the treatment of neurological disorders.
    本发明涉及哒嗪并[4,5-b]喹啉、 及其药用盐,它们是兴奋性氨基酸拮抗剂,在治疗神经系统疾病等需要这种拮抗剂时非常有用。本发明进一步提供了含有哒嗪并[4,5-b]喹啉类活性成分的药物组合物,以及治疗神经系统疾病的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐